Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (61-70 of 328) with videos related to

Pageof 33
Sort By:
International Journal of Hematology|May 29, 2024
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in JapanNami Tagami, Michihiro Uchiyama, Kenshi Suzuki, et al.
International Journal of Hematology|August 18, 2005
Detection of API2-MALT1 fusion transcripts in cytologic specimens of patients with pulmonary mucosa-associated lymphoid tissue lymphomaHiroshi Inagaki, Chunmei Li, Mitsukuni Okabe, et al.
Cancer Research|June 3, 2006
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilegeTakashi Ishida, Toshihiko Ishii, Atsushi Inagaki, et al.
Drug Metabolism and Pharmacokinetics|February 3, 2020
Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documentsMasahiro Tohkin, Yoshiro Saito, Satomi Yagi, et al.
International Journal of Hematology|November 17, 2016
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 studyShinsuke Iida, Hirokazu Nagai, Gen Kinoshita, et al.
Leukemia Research|August 23, 2002
Lymphoid blastic crisis of chronic myelogenous leukaemia with inv(16)(p13;q22)Kazuya Tsuboi, Hirokazu Komatsu, Hiroshi Miwa, et al.
International Journal of Hematology|July 26, 2002
Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndromeKazuya Tsuboi, Makoto Yazaki, Hiroshi Miwa, et al.
Cancer Medicine|September 26, 2023
Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in JapanHiromi Hagiwara, Takafumi Nakayama, Hiroya Hashimoto, et al.
Internal Medicine (Tokyo, Japan)|December 12, 2017
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple MyelomaMasaki Ri, Kenshi Suzuki, Shinsuke Iida, et al.
International Journal of Hematology|June 24, 2017
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation studyShinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, et al.
Pageof 33

Showing results (61-70 of 328) with videos related to

Sort By:
Pageof 33
International Journal of Hematology|May 29, 2024
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in JapanNami Tagami, Michihiro Uchiyama, Kenshi Suzuki, et al.
International Journal of Hematology|August 18, 2005
Detection of API2-MALT1 fusion transcripts in cytologic specimens of patients with pulmonary mucosa-associated lymphoid tissue lymphomaHiroshi Inagaki, Chunmei Li, Mitsukuni Okabe, et al.
Cancer Research|June 3, 2006
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilegeTakashi Ishida, Toshihiko Ishii, Atsushi Inagaki, et al.
Drug Metabolism and Pharmacokinetics|February 3, 2020
Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documentsMasahiro Tohkin, Yoshiro Saito, Satomi Yagi, et al.
International Journal of Hematology|November 17, 2016
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 studyShinsuke Iida, Hirokazu Nagai, Gen Kinoshita, et al.
Leukemia Research|August 23, 2002
Lymphoid blastic crisis of chronic myelogenous leukaemia with inv(16)(p13;q22)Kazuya Tsuboi, Hirokazu Komatsu, Hiroshi Miwa, et al.
International Journal of Hematology|July 26, 2002
Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndromeKazuya Tsuboi, Makoto Yazaki, Hiroshi Miwa, et al.
Cancer Medicine|September 26, 2023
Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in JapanHiromi Hagiwara, Takafumi Nakayama, Hiroya Hashimoto, et al.
Internal Medicine (Tokyo, Japan)|December 12, 2017
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple MyelomaMasaki Ri, Kenshi Suzuki, Shinsuke Iida, et al.
International Journal of Hematology|June 24, 2017
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation studyShinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, et al.
Pageof 33